Scarica l'app Stockscreener
9.64
0.72%
-0.07
Korro Bio Inc Borsa (KRRO) Ultime notizie
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Formela Jean Francois Sells 48,690 Korro Bio Shares, Retains 132,650 Shares Post-Transaction - kalkinemedia.com
Nearly 49,000 Korro Bio (KRRO) shares sold by director-linked funds - Stock Titan
Korro Bio (KRRO) finance SVP’s 5-share sale comes under a preset trading plan - Stock Titan
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Three new hires get options to buy 5,000 Korro Bio shares - Stock Titan
Senior finance VP at Korro Bio (KRRO) sells 7,353 shares under 10b5-1 trading plan - Stock Titan
Korro Bio unveils OPERA platform to harness natural RNA editing for targeted protein repair - tradersunion.com
Korro Bio (KRRO) director’s 300-share sale via 10b5-1 plan - Stock Titan
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio (NASDAQ:KRRO) Director Sells $398,552.00 in Stock - MarketBeat
Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19 - Stock Titan
Balyasny Asset Management L.P. Reduces Stake in Korro Bio Inc (K - GuruFocus
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing - TipRanks
Korro Bio (NASDAQ:KRRO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Form 8K Korro Bio Inc For: 19 August By Investing.com - Investing.com Nigeria
Korro Bio Advances KRRO-121 Into First Human Trial - TipRanks
Korro Bio, Inc. Announces Submission To Australian Alfred Health Human Ethics Committee To Initiate First-In-Human Phase 1/2 Clinical Trial For KRRO-121 - marketscreener.com
Korro (KRRO) Quarter in Focus: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading - vinanet.vn
KRRO Q2 2026 Earnings: Wider-Than-Expected Loss Avoided as Cost Discipline Drives 27.65% EPS BeatEarnings Yield Analysis - vinanet.vn
Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock - MarketBeat
Korro Bio director Jean Francois Formela sells $29,916 in shares By Investing.com - Investing.com Australia
Korro Bio director Jean Francois Formela sells $29,916 in shares - Investing.com
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock - MarketBeat
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock - Investing.com
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock By Investing.com - Investing.com Canada
Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase - Stock Titan
HC Wainwright Has Strong Estimate for Korro Bio Q3 Earnings - marketbeat.com
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - Yahoo Finance
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders - webull.com
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO) - theglobeandmail.com
Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS - marketbeat.com
Korro Bio (NASDAQ:KRRO) Upgraded at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Cantor Fitzgerald Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Korro Bio, Inc. expected to post a loss of $1.43 a shareEarnings Preview - TradingView
William Blair Maintains Korro Bio(KRRO.US) With Buy Rating - Moomoo
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook - Investing.com UK
Korro Bio Refines Capital Structure with Exchange Agreement - The Globe and Mail
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio earnings beat by $0.24, revenue topped estimates - Investing.com Canada
Korro Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Korro Bio Reports $18.9 Million Q2 Net Loss - Quiver Quantitative
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Korro Bio Swaps 1.0M Shares for Pre-Funded Warrants to Venrock at $0.001 Exercise Price - TradingView
Korro Bio, Inc. Q2 2026: Revenue $0M, Net loss $(18.9)M, EPS $(1.07) — 10-Q Summary - TradingView
Korro Bio (KRRO) CEO sells 5,802 shares of stock to cover taxes - Stock Titan
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):